Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers
2013
Purpose
Midostaurin (PKC412), a multitargeted tyrosine kinase inhibitor that targets FMS-related tyrosine kinase 3 and KIT, is in clinical trials for the treatment for acute myeloid leukemia and advanced systemic mastocytosis. In vitro studies showed that midostaurin is predominantly metabolized by cytochrome P450 3A4 (CYP3A4) and that midostaurin inhibits and/or induces the same enzyme. Here, we address the clinical relevance of CYP3A4-related drug–drug interactions with midostaurin as either a “victim” or “perpetrator.”
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
24
References
55
Citations
NaN
KQI